Comparison
Liraglutide vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
204656-20-2
no data
Molecular weight
3751 g/mol
888 g/mol
Half-life
13 h
no data
Sequence
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGAc-LKKTETQMechanism of action
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
5
3
of which in humans
4
0
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
1
2